Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines of therapy.
https://finance.yahoo.com/news/cellectars-blood-cancer-therapy-succeeds-114037386.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.